How proteins age
Physiological processes in the body are in large part determined by the composition of secreted proteins found in the circulatory systems, including the blood. Each of the hundreds of proteins in the blood has a specific life span that determines its unique range of abundance. In fact, measurements of their quantities and activities contribute to many clinical diagnoses. However, the way in which normal protein concentrations in the blood are determined and maintained has been a mystery for decades.
Biomedical scientists at UC Santa Barbara and the Sanford-Burnham-Prebys (SBP) Medical Discovery Institute have now discovered a mechanism by which secreted proteins age and turn over at the end of their life spans. Their findings, which shed light on a crucial aspect of health and disease, appear in Proceedings of the National Academy of Sciences.
"This is a fundamental advance that is broadly applicable and provides an understanding of how secreted proteins, which are involved in many important physiological processes, normally undergo molecular aging and turnover," said senior author Jamey Marth, director of UCSB's Center for Nanomedicine and a professor in the campus's Department of Molecular, Cellular, and Developmental Biology.
"When a secreted protein is made, it has a useful life span and then it must be degraded - the components are then basically recycled," added Marth, also a professor at the SBP Medical Discovery Institute in La Jolla, California. "We can now see how the regulation and alteration of secreted protein aging and turnover is able to change the composition of the circulatory system and thereby maintain health as well as contribute to various diseases."
This newly discovered mechanism encompasses multiple factors, including circulating enzymes called glycosidases. These enzymes progressively remodel N-glycans, which are complex structures of monosaccharide sugars linked together and attached to virtually all secreted proteins.
It is the N-glycan structure itself that identifies the protein as nearing the end of its life span. Subsequently, multiple receptors known as lectins - carbohydrate-binding proteins - recognize these aged proteins and eliminate them from circulation.
Marth and colleagues identified more than 600 proteins in the bloodstream that exhibit molecular signs of undergoing this aging and turnover process. Many of these proteins are regulators of proteolysis (the breakdown of proteins), blood coagulation and immunity.
Honing in on individual examples, the researchers were able to track each of them through time and watch the process unfold. "In these studies, we further saw that the different life spans of distinct proteins are accounted for by the different rates of aging due to N-glycan remodeling," said lead author Won Ho Yang, a postdoctoral associate at UCSB's Center for Nanomedicine and SBP.
"Altering this aging and turnover mechanism is the fastest way to change the abundance of a secreted protein, which we increasingly note is occurring at the interface of health and disease," Marth explained. "In retrospect from published literature and from studies in progress, we can now see how sepsis, diabetes and inflammatory bowel disorders can arise by the targeted acceleration or deceleration of secreted protein aging and turnover.
"The discovery of this mechanism provides a unique window into disease origins and progression," Marth added. "It has been known that circulating glycosidase enzyme levels are altered in diseases such as sepsis, diabetes, cancer and various inflammatory conditions. The resulting changes in the composition and function of the circulatory systems, including the blood and the lymphatic systems, can now be identified and studied. We are beginning to see previously unknown molecular pathways and connections in the onset and progression of disease."
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Category:PDE5_inhibitors
Mayo Clinic researchers map prostate cancer relapse - By using C-11 choline PET and MRI
Researchers discover immunity genes that give frogs resistance to deadly fungus
